121 completed, 25 unknown, 15 terminated, 7 withdrawn. 47 Phase 3, 41 Phase 2, 35 Phase 4, 32 Not applicable, 21 Phase 1.
Follow Aprepitant: new trials by email Literature Review of Aprepitant trials Research Report on Aprepitant
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Aprepitant for the Treatment of CLIFAHDD Aprepitant Powder for Oral Suspension - CLIFAHDD, Congenital Contractures of the Limbs and Face, Hypotonia, and Developmental Delay | Early Phase 1 | Recruiting | The University of Texas Health Science Center at San Antonio | 5 | 2026-10-31 | 2026-10-05 |
| QLM2010 Comparative Pharmacokinetic Study With 2-Minute Intravenous Administration apripitant and palonosetron injectable emulsion, palonosetron hydrochloride injection, apripitant injection (CINVANTI) - Chemotherapy-Induced Nausea and Vomiting (CINV) | Phase 1 | Not yet recruiting | Qilu Pharmaceutical (Hainan) Co., Ltd. | 42 | 2026-09-01 | 2026-09-14 |
| A Simplified Regimen to Prevent Nausea and Vomiting Using Netupitant/Palonosetron in Germ Cell Cancer Patients Receiving Chemotherapy Netupitant/Palonosetron Hydrochloride, Ondansetron (Control), Aprepitant - Germ Cell Cancer | Early Phase 1 | Not yet recruiting | Ottawa Hospital Research Institute | 10 | 2026-08-01 | 2026-06-23 |
| Aprepitant to Improve Same Day Discharge for TKA Aprepitant Injection, Ondansetron (Zofran), Dexamethasone - PONV | Phase 4 | Not yet recruiting | Endeavor Health | 350 | 2026-07-01 | 2026-06-10 |
| Effect of Aprepitant on Post-operative Nausea and Vomiting in Otologic Surgery Aprepitant, Placebo - Otologic Disease | Phase 4 | Not yet recruiting | Sir Mortimer B. Davis - Jewish General Hospital | 100 | 2026-06-01 | 2026-01-28 |
| Adding Aprepitant to a Multimodal Strategy for the Prevention of Postoperative Nausea and Vomiting in High-risk Outpatient Surgical Patients Aprepitant 40mg, Placebo - Nausea and Vomiting, Postoperative, Prevention | Phase 3 | Completed | Centre hospitalier de l'Université de Montréal (CHUM) | 260 | 2026-02-27 | 2026-08-27 |
| Aprepitant in the Management of Immune Checkpoint Inhibitors Pruritus in Solid Cancer Patients EMEND® (EE mend) (aprepitant) capsules (80mg +125mg) Marketing Authorization Holder and Importer: Merck Sharp & Dohme (Israel-1996) Company Ltd. - Pruritus | Phase 1 | Not yet recruiting | Rabin Medical Center | 30 | 2025-05-30 | 2025-04-17 |
| Aprepitant Treatment to Prevent Postoperative Nausea and Vomiting in Children Undergoing Scoliosis Surgery Aprepitant, Placebo - Spinal Fusion, Nausea and Vomiting, Postoperative | Phase 2 | Recruiting | IWK Health Centre | 100 | 2025-03-17 | 2026-04-27 |
| Efficacy and Safety Study of Aprepitant Injection for Prevention of Post-operative Nausea and Vomiting Aprepitant Injection, Aprepitant Injection Placebo - Post-operative Nausea and Vomiting (PONV) | Phase 3 | Unknown | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. | 486 | 2024-10-28 | 2024-08-09 |
| Aprepitant Plus Granisetron and Dexamethasone for the Prevention of Vomiting in Patients With HAIC Therapy for HCC Aprepitant in combination with granisetron and dexamethasone, Granisetron and dexamethasone - Hepatocellular Carcinoma | Phase 3 | Unknown | Guangxi Medical University | 300 | 2024-07-01 | 2024-01-23 |
| Aprepitant and Ondansetron Monotherapy or Combination for Postoperative Nausea and Vomiting in Thyroid Cancer Ondansetron 8mg, Aprepitant 125 mg - Thyroid Cancer | Phase 4 | Completed | The First Affiliated Hospital of Zhengzhou University | 600 | 2024-07-01 | 2025-01-22 |
| Prevention and Treatment of CINV Caused by TC Regimen in Gynecological Malignant Tumor Patients Aprepitant Injection - Gynecological Tumor, Ovarian Cancer | Phase 3 | Completed | Sichuan Cancer Hospital and Research Institute | 143 | 2024-05-31 | 2025-12-04 |
| Diagnostic and Therapeutic Potential of Substance P/ NK1R Receptor in Primary Dysmenorrhea Ibuprofen and Aprepitant - Primary Dysmenorrhea | Phase 3 | Completed | Lahore Medical Research Center, LLP | 40 | 2024-03-15 | 2025-02-21 |
| Efficacy and Safety Study of Aprepitant Injection for Prevention of Post-operative Nausea and Vomiting Aprepitant Injection, Aprepitant Injection Placebo - Postoperative Nausea and Vomiting | Phase 3 | Completed | Qilu Pharmaceutical (Hainan) Co., Ltd. | 518 | 2024-02-02 | 2025-04-23 |
| Comparative Pharmacokinetic Study of Aprepitant Injection in Humans Test (T) Aprepitant injection, Reference (R) Aprepitant injection - Healthy | Phase 1 | Unknown | The Affiliated Hospital of Qingdao University | 24 | 2024-01-23 | 2024-01-26 |
| Ondanstron Weekly vs Every 3 Weeks for Prevention of Nausea and Vomiting Induced by Chemotherapy Combined With PD-1 Blockade Ondansetron every 3 weeks, Aprepitant, Dexamethasone - Nausea With Vomiting Chemotherapy-Induced | Not applicable | Recruiting | Hubei Cancer Hospital | 98 | 2023-12-01 | 2024-02-29 |
| Triple Therapy of Dexamethasone, Palonosetron, and Fosaprepitant As PONV Prevention fosaprepitant, normal saline - Postoperative Nausea and Vomiting, Gynecologic Surgical Procedures | Not applicable | Enrolling by invitation | Samsung Medical Center | 144 | 2023-08-18 | 2025-03-30 |
| Efficacy and Safety of Intravenous Versus Oral 5-HT3 Antagonists Combined With NK-1 Receptor Antagonists for the Prevention of CINV in Breast Cancer Aprepitant, Palonosetron, Fosaprepitant - Breast Cancer, Chemotherapy-induced Nausea and Vomiting | Phase 4 | Not yet recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 1028 | 2023-07-01 | 2023-05-03 |
| Recommendations of Enhanced Recovery Interventions for Patient's Clinical Team and Collection of Associated Data Neuraxial Analgesia, Regional Block 1: Paravertebral, Perphenazine - Perioperative Optimization | Phase 3 | Completed | Jennifer Holder-Murray | 3395 | 2023-05-15 | 2026-05-28 |
| The Effect of Aprepitant Reducing Postoperative Nausea and Vomiting Aprepitant, Placebo - Obesity, Nausea and Vomiting, Postoperative | Phase 4 | Unknown | Hospital General Tlahuac | 400 | 2022-12-01 | 2023-03-16 |
Showing 20 of 178. Sign in to see all of them.
Vomiting (89) · Nausea (55) · Postoperative Nausea and Vomiting (34) · Breast Neoplasms (10) · Neoplasms (10) · Depressive Disorder, Major (9) · Lymphoma (9) · Multiple Myeloma (7) · Leukemia, Myeloid, Acute (6) · Lymphoma, Non-Hodgkin (6) · Ovarian Neoplasms (6) · Pruritus (5) · Carcinoma, Non-Small-Cell Lung (4) · Leukemia (4) · Myeloproliferative Disorders (4)
Merck Sharp & Dohme LLC (31) · University of Pennsylvania (5) · M.D. Anderson Cancer Center (3) · Sun Yat-sen University (3) · All India Institute of Medical Sciences (2) · Chinese Academy of Medical Sciences (2) · Dartmouth-Hitchcock Medical Center (2) · Duke University (2) · Fudan University (2) · Instituto do Cancer do Estado de São Paulo (2) · Mayo Clinic (2) · NYU Langone Health (2) · Northwell Health (2) · OHSU Knight Cancer Institute (2) · Ottawa Hospital Research Institute (2)
United States (69) · China (15) · Canada (10) · Italy (6) · South Korea (6) · Germany (4) · India (4) · Russia (4) · Brazil (3) · Hungary (3) · Japan (3) · Mexico (3) · Netherlands (3) · Poland (3) · Spain (3)
Pablo Tebas, MD (3) · David M. Burger, PharmD PhD (2) · Fausto Roila, MD (2) · Ajeet Gajra, MD FACP (1) · Alice P Chen, M.D. (1) · Andrew Grigg, Professor (1) · Arthur Blackstock (1) · Ashish Sinha, MD (1) · Ashraf S Habib, MBBCH, FRCA (1) · Barbara A. Murphy, MD (1) · Barbara J Mason, Ph.D. (1) · Barbara J. Mason, Ph.D. (1)
PMID 16248986, PMID 16314401, PMID 22141732, PMID 22995650, PMID 23062719, PMID 25770814, PMID 10824073, PMID 11030465, PMID 11497388, PMID 12712486, PMID 12736106, PMID 12784346, PMID 14504060, PMID 14559886, PMID 14635083, PMID 14966097, PMID 15837996, PMID 16014882, PMID 16766588, PMID 16918326, PMID 17085262, PMID 17298105, PMID 17522250, PMID 17535226, PMID 18048820, PMID 18181978, PMID 19568773, PMID 19692680, PMID 19775450, PMID 19793151, PMID 20067329, PMID 20493771, PMID 20532044, PMID 20544226, PMID 20718754, PMID 20820812, PMID 20871394, PMID 21039410, PMID 21081776, PMID 21630130, PMID 21783417, PMID 21931661, PMID 22024310, PMID 22245954, PMID 22260216, PMID 22512843, PMID 22739139, PMID 22850916, PMID 22870909, PMID 22915652
2008 (4), 2018 (2), P30CA022453 (2), R01DA030988 (2), U01MH090325 (2), 2009 (1), K01DA025073 (1), P30CA014089 (1), P30CA016086 (1), R01DA027031 (1), R01DA027151 (1), U01DK073974 (1), U01DK073975 (1), U01DK073983 (1), U01DK073985 (1)